Recent Faculty Publications

Our research, which reflects the wide scope of interests encompassed by our division, frequently appears in leading academic journals.

Matthew Hudson, MD

Hudson MJ, Park SC, Mathers A, Parikh H, Glowicz J, Dar D, Nabili M, LiPuma JJ, Bumford A, Pettengill MA, Sterner MR, Paoline J, Tressler S, Peritz T, Gould J, Hutter SR, Moulton-Meissner H, Perkins KM. (2022) Outbreak of Burkholderia stabilis Infections Associated with Contaminated Nonsterile, Multiuse Ultrasound Gel - 10 States, May-September 2021. MMWR. Morbidity and mortality weekly report (Dec), 71(48): 1517-1521. doi:10.15585/mmwr.mm7148a3

View full profile

Thomas Mahl, MD

Yang K, Nallapeta N, Hossein-Javaheri N, Carlson A, Quigley B, Mahl T. (2025) Predictors and prognosticators of outcomes in alcoholic hepatitis: A retrospective single center study. World journal of hepatology (Feb), 17(2): 102152. doi:10.4254/wjh.v17.i2.102152
Duve RJ, Moga TG, Yang K, Mahl TC, Dove E. (2023) Hepatic Amyloidosis With Multiorgan Involvement. ACG case reports journal (Apr), 10(4): e00999. doi:10.14309/crj.0000000000000999
Yang K, Moga T, Nallapeta NS, Duve R, Miranda CJ, Ismail M, Mahl T. (2022) Severe Cholestatic Drug-Induced Liver Injury With Cephalosporin Use. Cureus (Dec), 14(12): e32262. doi:10.7759/cureus.32262

View full profile

Anthony Martinez, MD

Sulkowski MS, Martinez A, Tyson GL, Scholz K, Franco RA, Kohli A, Julius SF, Deming P, Fink SA, Lynch K, Roytman M, Stainbrook TR, Turner MD, Viera-Briggs M, Ramers CB. (2024) Leveraging opportunities for treatment/user simplicity (LOTUS): Navigating the current treatment landscape for achieving hepatitis C virus elimination among persons who inject drugs. Journal of viral hepatitis (Jun), 31(6): 342-356.
Martinez A, Khan T, Dylla DE, Marcinak J, Collins M, Saget B, Conway B. (2023) Reported adverse events related to use of hepatitis C virus direct-acting antivirals with opioids: 2017-2021. Harm reduction journal (Oct), 20(1): 142. doi:10.1186/s12954-023-00874-y
Mukherjee D, Collins M, Dylla DE, Kaur J, Semizarov D, Martinez A, Conway B, Khan T, Mostafa NM. (2023) Assessment of Drug-Drug Interaction Risk Between Intravenous Fentanyl and the Glecaprevir/Pibrentasvir Combination Regimen in Hepatitis C Patients Using Physiologically Based Pharmacokinetic Modeling and Simulations. Infectious diseases and therapy (Aug), 12(8): 2057-2070. doi:10.1007/s40121-023-00830-0

View full profile

Anoop Prabhu, M.D.

View full profile

Navpreet Rana

View full profile

Andrew Talal, MD, MPH

Nassar M, Baraka B, Talal AH. (2025) Innovative Approaches in Predicting Outcomes for Rectal Neuroendocrine Tumors. World J Gastroenterol (Feb), 31(6) doi:https://doi.org/10.3748/wjg.v31.i6.100517
Patel P, Wells MT, Wethington E, Shapiro M, Parvez Y, Kapadia SN, Talal AH. (2024) United States Provider Experiences With Telemedicine for Hepatitis C Treatment: A Nationwide Survey. Journal of viral hepatitis (Dec), 31(12): 873-879.
Eum S, Vernacchia NP, Doughty N, Mehrzad S, Talal AH, Chalabianloo F, Kharasch ED. (2024) Methadone metabolism and cytochrome P450 polymorphisms: A systematic review and meta-analysis. Expert Opinion on Drug Metabolism and Toxicology (Nov)1-16. doi:doi.org/10.1080/17425255.2024.2432664

View full profile

Nahel Altaf Tunio

View full profile